WallStSmart

Aurora Cannabis Inc (ACB)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 3803% more annual revenue ($14.56B vs $373.12M). VTRS leads profitability with a -2.0% profit margin vs -22.5%. VTRS earns a higher WallStSmart Score of 48/100 (D+).

ACB

Avoid

34

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -7.92

VTRS

Hold

48

out of 100

Grade: D+

Growth: 3.3Profit: 2.5Value: 8.3Quality: 4.5
Piotroski: 4/9Altman Z: 0.80
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ACB.

VTRSUndervalued (+33.6%)

Margin of Safety

+33.6%

Fair Value

$24.30

Current Price

$17.17

$7.13 discount

UndervaluedFair: $24.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACB2 strengths · Avg: 9.5/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1510/10

Growing faster than its price suggests

Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Areas to Watch

ACB4 concerns · Avg: 2.5/10
Market CapQuality
$202.80M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
2.3%3/10

Operating margin of 2.3%

Return on EquityProfitability
-15.5%2/10

ROE of -15.5% — below average capital efficiency

EPS GrowthGrowth
-94.7%2/10

Earnings declined 94.7%

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-2.0%2/10

ROE of -2.0% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-2.0%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : ACB

The strongest argument for ACB centers on Price/Book, Debt/Equity.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.15 suggests the stock is reasonably priced for its growth.

Bear Case : ACB

The primary concerns for ACB are Market Cap, Operating Margin, Return on Equity.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

ACB carries more volatility with a beta of 1.33 — expect wider price swings.

VTRS is growing revenue faster at 8.1% — sustainability is the question.

VTRS generates stronger free cash flow (348M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTRS scores higher overall (48/100 vs 34/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aurora Cannabis Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Aurora Cannabis Inc. produces and distributes medical cannabis products globally. The company is headquartered in Edmonton, Canada.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?